163 related articles for article (PubMed ID: 19068212)
1. Differential sensitivities of CaV1.2 IIS5-S6 mutants to 1,4-dihydropyridine analogs.
Hui K; Kwok TC; Kostelecki W; Leen J; Roy PJ; Feng ZP
Eur J Pharmacol; 2009 Jan; 602(2-3):255-61. PubMed ID: 19068212
[TBL] [Abstract][Full Text] [Related]
2. Key roles of Phe1112 and Ser1115 in the pore-forming IIIS5-S6 linker of L-type Ca2+ channel alpha1C subunit (CaV 1.2) in binding of dihydropyridines and action of Ca2+ channel agonists.
Yamaguchi S; Zhorov BS; Yoshioka K; Nagao T; Ichijo H; Adachi-Akahane S
Mol Pharmacol; 2003 Aug; 64(2):235-48. PubMed ID: 12869628
[TBL] [Abstract][Full Text] [Related]
3. Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.
Huber I; Wappl E; Herzog A; Mitterdorfer J; Glossmann H; Langer T; Striessnig J
Biochem J; 2000 May; 347 Pt 3(Pt 3):829-36. PubMed ID: 10769189
[TBL] [Abstract][Full Text] [Related]
4. A region of N-type Ca(2+) channel critical for blockade by the dihydropyridine amlodipine.
Miyashita Y; Furukawa T; Kamegaya E; Yoshii M; Nukada T
Eur J Pharmacol; 2010 Apr; 632(1-3):14-22. PubMed ID: 20097194
[TBL] [Abstract][Full Text] [Related]
5. Distinctions in the molecular determinants of charged and neutral dihydropyridine block of L-type calcium channels.
Lacinová L; An RH; Xia J; Ito H; Klugbauer N; Triggle D; Hofmann F; Kass RS
J Pharmacol Exp Ther; 1999 Jun; 289(3):1472-9. PubMed ID: 10336541
[TBL] [Abstract][Full Text] [Related]
6. Distinct properties of amlodipine and nicardipine block of the voltage-dependent Ca2+ channels Cav1.2 and Cav2.1 and the mutant channels Cav1.2/dihydropyridine insensitive and Cav2.1/dihydropyridine sensitive.
Lin M; Aladejebi O; Hockerman GH
Eur J Pharmacol; 2011 Nov; 670(1):105-13. PubMed ID: 21910984
[TBL] [Abstract][Full Text] [Related]
7. Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes.
Furukawa T; Nukada T; Namiki Y; Miyashita Y; Hatsuno K; Ueno Y; Yamakawa T; Isshiki T
Eur J Pharmacol; 2009 Jun; 613(1-3):100-7. PubMed ID: 19401195
[TBL] [Abstract][Full Text] [Related]
8. Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes.
Furukawa T; Yamakawa T; Midera T; Sagawa T; Mori Y; Nukada T
J Pharmacol Exp Ther; 1999 Nov; 291(2):464-73. PubMed ID: 10525060
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of type A GABA receptors by L-type calcium channel blockers.
Das P; Bell-Horner CL; Huang RQ; Raut A; Gonzales EB; Chen ZL; Covey DF; Dillon GH
Neuroscience; 2004; 124(1):195-206. PubMed ID: 14960351
[TBL] [Abstract][Full Text] [Related]
10. A genetic screen for dihydropyridine (DHP)-resistant worms reveals new residues required for DHP-blockage of mammalian calcium channels.
Kwok TC; Hui K; Kostelecki W; Ricker N; Selman G; Feng ZP; Roy PJ
PLoS Genet; 2008 May; 4(5):e1000067. PubMed ID: 18464914
[TBL] [Abstract][Full Text] [Related]
11. Serine residue in the IIIS5-S6 linker of the L-type Ca2+ channel alpha 1C subunit is the critical determinant of the action of dihydropyridine Ca2+ channel agonists.
Yamaguchi S; Okamura Y; Nagao T; Adachi-Akahane S
J Biol Chem; 2000 Dec; 275(52):41504-11. PubMed ID: 11022040
[TBL] [Abstract][Full Text] [Related]
12. Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore.
Peterson BZ; Catterall WA
Mol Pharmacol; 2006 Aug; 70(2):667-75. PubMed ID: 16675661
[TBL] [Abstract][Full Text] [Related]
13. L-type calcium channels: asymmetrical intramembrane binding domain revealed by variable length, permanently charged 1,4-dihydropyridines.
Bangalore R; Baindur N; Rutledge A; Triggle DJ; Kass RS
Mol Pharmacol; 1994 Oct; 46(4):660-6. PubMed ID: 7969044
[TBL] [Abstract][Full Text] [Related]
14. Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca(2+) channels.
Hockerman GH; Dilmac N; Scheuer T; Catterall WA
Mol Pharmacol; 2000 Dec; 58(6):1264-70. PubMed ID: 11093762
[TBL] [Abstract][Full Text] [Related]
15. Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2.
Dilmac N; Hilliard N; Hockerman GH
Mol Pharmacol; 2004 Nov; 66(5):1236-47. PubMed ID: 15286207
[TBL] [Abstract][Full Text] [Related]
16. A small-molecule screen in C. elegans yields a new calcium channel antagonist.
Kwok TC; Ricker N; Fraser R; Chan AW; Burns A; Stanley EF; McCourt P; Cutler SR; Roy PJ
Nature; 2006 May; 441(7089):91-5. PubMed ID: 16672971
[TBL] [Abstract][Full Text] [Related]
17. Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity.
Schaller D; Gündüz MG; Zhang FX; Zamponi GW; Wolber G
Eur J Med Chem; 2018 Jul; 155():1-12. PubMed ID: 29843108
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of voltage-gated L-type calcium channels by labedipinedilol-A involves protein kinase C in rat cerebrovascular smooth muscle cells.
Wu BN; Chen ML; Dai ZK; Lin YL; Yeh JL; Wu JR; Chen IJ
Vascul Pharmacol; 2009; 51(2-3):65-71. PubMed ID: 19298869
[TBL] [Abstract][Full Text] [Related]
19. Molecular requirements for L-type Ca2+ channel blockade by testosterone.
Scragg JL; Dallas ML; Peers C
Cell Calcium; 2007 Jul; 42(1):11-5. PubMed ID: 17173968
[TBL] [Abstract][Full Text] [Related]
20. Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors.
Thayer SA; Welcome M; Chhabra A; Fairhurst AS
Biochem Pharmacol; 1985 Jan; 34(2):175-80. PubMed ID: 2981533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
